{"organizations": [], "uuid": "6bedf978e62c67bc0891ad6671784500a6b94d6a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-sucampo-pharmaceuticals-received-n/brief-sucampo-pharmaceuticals-received-notification-from-fda-that-it-has-extended-pdufa-goal-date-by-3-months-idUSFWN1OX0HR", "country": "US", "domain_rank": 408, "title": "BRIEF-Sucampo Pharmaceuticals Received Notification From FDA That It Has Extended PDUFA Goal Date By 3 Months", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-02T16:36:00.000+02:00", "replies_count": 0, "uuid": "6bedf978e62c67bc0891ad6671784500a6b94d6a"}, "author": "", "url": "https://www.reuters.com/article/brief-sucampo-pharmaceuticals-received-n/brief-sucampo-pharmaceuticals-received-notification-from-fda-that-it-has-extended-pdufa-goal-date-by-3-months-idUSFWN1OX0HR", "ord_in_thread": 0, "title": "BRIEF-Sucampo Pharmaceuticals Received Notification From FDA That It Has Extended PDUFA Goal Date By 3 Months", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-sucampo pharmaceuticals", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}, {"name": "sucampo pharmaceuticals inc", "sentiment": "none"}, {"name": "months reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 36 PM / Updated 5 minutes ago BRIEF-Sucampo Pharmaceuticals Received Notification From FDA That It Has Extended PDUFA Goal Date By 3 Months Reuters Staff 1 Min Read \nJan 2 (Reuters) - Sucampo Pharmaceuticals Inc: \n* SUCAMPO PHARMACEUTICALS - ON DEC 28, RECEIVED NOTIFICATION FROM U.S. FDA THAT IT HAS EXTENDED PDUFA GOAL DATE BY 3 MONTHS FOR SNDA FOR LUBIPROSTONE \n* SUCAMPO PHARMACEUTICALS - EXTENDED USER FEE GOAL DATE FOR THE SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR LUBIPROSTONE IS APRIL 28, 2018- SEC FILING Source text :[ bit.ly/2Ctygjm ] Further company coverage:", "external_links": [], "published": "2018-01-02T16:36:00.000+02:00", "crawled": "2018-01-02T16:43:11.039+02:00", "highlightTitle": ""}